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Abstract
Objective Challenges can exist when framing the decision question in a cost-effectiveness analysis, particularly when there 
is disagreement among experts on relevant comparators. Using prostate cancer screening and recent developments in risk 
stratification, early-detection biomarkers, and diagnostic technologies as a case study, we report a modified Delphi approach 
to handle decision-question uncertainty.
Methods The study involved two rounds of anonymous online questionnaires to identify the prostate cancer screening strate-
gies that international researchers, clinicians and decision makers felt important to consider in a cost-effectiveness model. 
Both purposive and snowball sampling were used to recruit experts. The questionnaire was based on a review of the literature 
and was piloted for language, comprehension and ease of use prior to dissemination. In Round 1, respondents indicated their 
preferred screening strategy (including no screening) through a series of multiple-choice questions. The responses informed 
a set of 13 consensus statements, which respondents ranked their agreement with on a 9-point Likert scale (Round 2). Con-
sensus was considered reached if > 70% of participants indicated agreement and < 15% indicated disagreement.
Results Twenty participants completed Round 1 and 17 completed Round 2. Consensus was shown towards comparing no 
formal screening, age-based, and risk-based strategies. The risk-based approaches included screening only higher-risk men, 
using shorter screening intervals for higher-risk men, screening higher-risk men at an earlier age, and tailoring screening 
intervals based on prostate-specific antigen (PSA) level at a previous test. There was agreement that inclusion of MRI in the 
pathway should be considered, but disagreement on the inclusion of new biomarkers.
Conclusion In disease areas where technologies are rapidly evolving, a modified Delphi approach provides a useful tool to 
identify relevant comparators in an economic evaluation.
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1  Introduction/Background
To determine whether new healthcare innovations should 
be implemented at a national level, evidence on both 
long-term effectiveness and cost effectiveness is required. 
Generally, it is recommended that cost-effectiveness mod-
els include all possible comparators, or clearly justify their 
exclusion [1–3]. Philips et al. [2] state that this should 
be “based on literature reviews and expert opinion and 
will include evidence from local guidelines and treatment 
patterns”.
As with all health care interventions, cost-effectiveness 
models for screening interventions include many compo-
nents that have the potential to change over time. The 
frequency of screening, population to screen, diagnostic 
test or tests used, and their order and combination are all 
subject to changing practice and can make identifying 
all possible comparators, especially “what is relevant?”, 
challenging. Prostate cancer screening in particular is an 
area where considerable uncertainty as to what the com-
parators in a cost-effectiveness analysis should be exists. 
There is an ongoing debate around whether to screen and 
if so, who, how and how often in an era of relatively rapid 
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Key Points 
This study has demonstrated an application of the 
modified Delphi approach to determine relevant options 
for comparison in a cost-effectiveness analysis, where 
uncertainty exists.
Using prostate cancer as a case study, the method was 
successful in identifying the prostate cancer screening 
strategies that are relevant to researchers, clinicians and 
decision makers.
2  Methods
The Delphi technique provides a systematic method of gain-
ing consensus from a group of experts through collecting 
and aggregating informed judgments over multiple itera-
tions [16, 17]. Expert participants are asked to provide their 
opinions in sequential questionnaires, given group feedback 
from the previous round. Feedback from sequential rounds 
encourages participants to reassess, alter and/or develop 
opinions. Responses are anonymous to ensure that no indi-
vidual dominates the process [18].
Using a modified Delphi design means that, rather 
than consulting an expert panel to generate the questions 
addressed in the study, the researcher collects the initial 
question(s) through some other means, such as a literature 
review, and presents them to the panel to begin the consen-
sus seeking process [19]. The modified Delphi technique 
used in our study is described in Fig. 1.
2.1  Participants and Recruitment
In identifying experts, European Food Safety Authority guid-
ance [17] was used, in that the research team first decided 
what type of expertise was needed to answer the questions 
(i.e. expertise in prostate cancer early detection, treatment, 
modelling or the role of genetics in prostate cancer risk), and 
then attempted to identify individuals with this particular 
expertise. To identify and recruit experts to take part in the 
modified Delphi process, purposive sampling was used. This 
focuses on the views of those able to provide in-depth knowl-
edge of the topic of interest [20]. In-depth knowledge related 
to factors such as on-the-job experience and peer-reviewed 
academic output. The participants worked in a variety of insti-
tutions including Universities in the UK, Sweden, Finland, the 
Netherlands and the US, cancer centres in the US, NHS trusts, 
Public Health England, and the Institute of Cancer Research. 
The selection of participants from a variety of backgrounds 
and institutions was important to encourage diversity of opin-
ions. The purposive sampling was complemented with snow-
ball sampling, whereby the contacts were asked to suggest 
others within or outside their organisations that might offer 
insight [21]. Prior research experience, clinical focus, country, 
and age range were included in the questionnaire so that the 
impact of these factors on preferences could be assessed.
Contacts were first sent a detailed participant informa-
tion sheet (Supplementary material 1, see electronic sup-
plementary material [ESM]), explaining that the aim of the 
study was to help the study team understand the prostate 
cancer screening strategies that are relevant to compare in a 
evolving practice and advancements in screening and test-
ing technologies.
Current practice in the UK, Europe and the US gen-
erally consists of opportunistic/unorganised prostate-
specific antigen (PSA) testing with a recommendation 
against formal screening [5–10]. This is because previ-
ous methods of relying solely on untargeted PSA testing 
have not clearly shown that the benefits of early detec-
tion using PSA testing outweigh the potential harms of 
overdiagnosis and overtreatment [11]. However, recent 
advancements in the identification of risk factors for 
aggressive disease, such as newly identified genetic var-
iants (polygenic risk) [12]; early detection biomarkers 
such as the Stockholm 3 panel (STHLM3) [13]; and new 
strategies to target diagnostic biopsy, including the use 
of multiparametric magnetic resonance imaging (mpMRI 
[14]), potentially offer new opportunities to reduce over-
diagnosis and overtreatment. The long-term effectiveness 
and cost effectiveness of these new approaches (indi-
vidually or in combination) in reducing overdiagnosis 
and mortality in prostate cancer screening has yet to be 
ascertained.
The gathering of expert opinion on the most relevant 
strategies in clinical practice, and therefore the most use-
ful strategies to compare in a cost-effectiveness model, is 
a recommended first step in many if not all guidelines on 
conceptualizing decision models [2–4, 15]. However, the 
methods to do so have not been clearly formulated. Taking 
current practice of opportunistic screening as the reference 
case, our aim was to provide a method to handle decision 
question uncertainty by using a modified Delphi approach 
to elicit which recent developments in prostate cancer 
screening are relevant for comparing in a cost-effectiveness 
analysis and will provide meaningful findings to decision 
makers.
Modified Delphi Approach to Gain Consensus on RelevantComparators in a Cost-Effectiveness Model
cost-effectiveness model, given the rapidly changing land-
scape in prostate cancer screening. The sheet also informed 
participants on why they were being asked to take part and 
what they would be required to do.
2.2  Step 1: Production of Questionnaire 
and Evidence Dossier
To identify the extent of the uncertainty in the decision 
question, a rapid review of the literature was carried out. 
The review involved identifying and summarising current 
UK and international guidelines on prostate cancer screen-
ing in terms of what diagnostic tools to use, the ages to 
start and stop screening and recommended screening fre-
quency. Recent large trials that addressed different aspects 
of screening, and which have informed these guidelines, 
were also identified. An evidence dossier providing an over-
view of relevant trials was produced using the review evi-
dence (Supplementary Material 2, see ESM). The evidence 
dossier was circulated to an advisory panel comprising two 
oncologists, two urologists, one GP, and two researchers in 
prostate cancer screening and clinical oncology (four from 
the UK and three from the US), to identify any missing 
evidence.
The findings from the review informed the development 
of the questionnaire, which centred around three primary 
domains of uncertainty: (1) the group of men that should be 
invited for screening; (2) how often they should be screened; 
and (3) which diagnostic procedures to use. These domains 
were considered basic starting points of any screening strat-
egy with the aim of the questionnaire being to clarify areas 
of uncertainty within these domains.
Although training was not provided to the participants 
in advance, the questionnaire was piloted for language, 
comprehension and ease of use on a smaller group com-
prising a clinical oncology researcher, a medical oncolo-
gist, a GP and a urologist. No difficulty was demonstrated 
in completing the questionnaire and the answers given 
indicated a good degree of understanding. Changes were 
made in response to their comments, such as a move away 
from a ranking of preferences within each question and 
towards the selection of one preferred approach. This 
enabled the experts’ preferences among the available 
options to be more clearly drawn out and was in response 
Fig. 1  Modified Delphi technique
 E. Keeney et al.
to comments that after a certain rank the experts had no 
real preference.
2.3  Step 2: Dissemination of Questionnaire
A web-administered version of the questionnaire was devel-
oped using REDCap electronic data capture tools hosted at 
the University of Bristol [22]. Links to the questionnaires 
and evidence dossier were circulated to the participants via 
email. The questionnaire was sent to 20 experts in the first 
instance, with seven additional participants included through 
snowball sampling. A minimum sample of 23 has been 
shown to be sufficient and reliable in Delphi surveys when 
experts are carefully selected [23]. Approval for the study 
was granted by the Faculty of Health Sciences Research Eth-
ics Committee of the University of Bristol (Approval refer-
ence number: 91622).
In Round 1, respondents were asked to indicate their 
preferred screening strategy through a series of questions. 
This included an option of ‘no screening’. Completion of 
these questions resulted in the generation of an automatic 
statement that summarised each respondent’s answers. An 
example of this can be seen in Box 1:
An updated questionnaire, in the form of 13 consensus 
statements, was then sent to the same key contacts from 
Round 1 and their lists of suggested contacts. The state-
ments were designed to clarify the respondent’s views from 
Round 1, with an emphasis on the strategies for inclusion 
in a cost-effectiveness model. Feedback from Round 1 was 
presented for each Round 2 item in the form of the number 
of participants choosing each option and a summary of com-
ments given. The first round was completed in November 
2019, and the second round in January 2020. As 2 months 
had passed since the first round, participants were given a 
reminder of their own choice.
As is common in Delphi procedures [24, 26], respond-
ents were requested to rank their agreement with the 13 
statements on a 9-point Likert scale (i.e. ranging from 1 = 
“strongly disagree” to 9 = “strongly agree”). Consensus on 
a statement was considered reached if scored 7 to 9 (mod-
erately agree, agree, or strongly agree) by >70% of partici-
pants and 1 to 3 (strongly disagree, disagree or moderately 
disagree) by <15% of all participants [24]. In place of con-
ducting further Delphi rounds, which were not deemed nec-
essary after considering the results of the first two rounds, 
more stringent criteria were also set (> 70% scoring an item 
8 or 9 and <15% scoring 1–3), to aid discussion on the most 
important aspects to participants, in line with a previous 
consensus process [25]. Within-group interrater agreement 
was assessed using the r*wg statistic with the rectangular 
null and maximum dissensus null distributions [27]. This is 
a commonly used statistic to quantify consensus in ratings 
on a Likert scale [28]. With this statistic r*wg ≥ 0.80 may 
be considered high enough agreement to establish interrater 
agreement with 10 or more raters.
3  Results
3.1  Round 1
3.1.1  Characteristics of Respondents
Twenty participants (74%) responded to the questionnaire, 
out of 27 invitees. The respondents were of varying ages 
with most being in the 45–64 years age bracket. Nine out 
of 20 (45%) respondents had over 20 years’ experience in 
Using a free-text section at the end of each question, 
respondents could add items they considered important but 
that were not already covered or indicate their uncertainty 
with regard to a particular question. An example of a com-
pleted questionnaire is available in Supplementary Material 
3 (see ESM).
2.4  Step 3: Updating of Questionnaire and Evidence 
Dossier
The first-round responses informed the content and modifi-
cation of an updated questionnaire (Round 2). At the end of 
Round 1, the percentage of participants choosing each item 
was summarised. Items were not considered in Round 2 if 
not chosen by any participant in Round 1. Nor were they 
included if chosen by >70% of participants, as consensus 
was already considered reached. Previous Delphi studies 
have also used this level of agreement [24]. New items were 
considered if suggested by > 10% of participants, also in line 
with a previous Delphi consensus process [25].
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followed by no screening (5/20 participants, 25%) and age-
based screening (4/20 participants, 20%) (Fig. 3a).
Risk-based screening was chosen by all five urologists 
and no screening was chosen by all of those involved in 
national screening services. No other trends were identi-
fied based on age, experience, or country of residence. 
Reasons given for preferring risk-based screening included 
“early detection and intervention for people with strong 
risk factors”, and “more scope for improvement as we 
learn to better estimate a man’s risk”. Reasons given for 
selecting age-based screening included preventing oppor-
tunistic screening in the “wrong” age ranges, and for sim-
plicity. All participants who selected ’no screening’ high-
lighted that this was due to a lack of current evidence that 
screening offers more benefit than harm.
The second question asked all participants who had 
indicated risk-based screening to be their preferred 
option which factor/s they thought risk should be based 
on. Multiple options could be chosen. Five of 11 partici-
pants who chose risk-based screening ticked all available 
options. The most popular option was family history of 
prostate cancer (chosen by 9 participants), followed by 
life expectancy > 10 years (based on a risk calculator) (8), 
Fig. 2  Characteristics of respondents—Round 1
their field. Responses were received from six oncologists, 
five urologists, three GPs, two public health specialists, two 
researchers with experience of modelling prostate cancer, 
and two people involved in UK national screening services. 
Four of the respondents had extensive experience in cancer 
epidemiology, and three of these were Professors in general 
epidemiology or in cancer epidemiology, specifically. Eleven 
out of 20 (55%) of the respondents were UK based (Fig. 2). 
As responses were received from participants with a range of 
expertise and backgrounds, 20 participants were considered 
sufficient to collect rich data and allow exploration of the 
screening strategies thought to be important.
3.1.2  Who Should Be Invited For Screening?
With the aim of determining the most relevant strategies 
to compare in a cost-effectiveness model, the first question 
asked what type of screening programme, if any, partici-
pants felt should be provided in the UK. Options included 
no screening, opportunistic screening, organised age-based 
screening and organised risk-based screening. No partici-
pant chose opportunistic screening. The most popular choice 
was risk-based screening, chosen by 11 participants (55%), 
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ethnicity (8), PSA at age 40 years above a certain thresh-
old (7) and polygenic risk (which provides an indication 
of whether someone might be genetically predisposed to 
developing prostate cancer) (7), giving an even spread of 
responses (Fig. 3b). Other suggestions were biomarkers 
and “germline high risk mutations”. Comments on this 
question centred around the understanding that "all availa-
ble risk factors which can be measured reliably and afford-
ably should be included" with the optimal combination of 
factors being unclear.
Fig. 3  Number of participants selecting each response to questions, 
a “What type of prostate cancer screening programme do you feel 
should be provided in the UK?”, b “If risk-based screening were to 
be provided what factor/s should risk be based on?”, c “Which PSA 
threshold do you think should be used to indicate further investiga-
tion?”, d “What further investigation should men with a raised PSA 
level have prior to being offered a biopsy?”, and e “Assuming some 
optimal strategy for inviting men to be screened has been adopted, 
how frequently do you think men should be screened?”
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3.1.3  Which Diagnostic Procedures?
The next question asked participants, if a screening pro-
gramme were to be implemented, which PSA threshold they 
thought should be used to indicate further investigation, with 
the options being 3 ng/mL, 4 ng/mL, 5 ng/mL, 6 ng/mL, 
7 ng/mL, 8.5 ng/mL, 10 ng/mL, and ’this should be based 
on age’. Five of 20 participants chose a threshold of 3 ng/mL 
and one chose a threshold of 5 ng/mL (Fig. 3c). In the ’other’ 
column, two participants suggested that the PSA threshold 
for investigation should be < 3 ng/mL, two suggested that 
PSA should be combined with other biomarkers, two sug-
gested that risk calculators should be used in place of PSA 
and two commented that they did not support any screening.
Comments on this question generally reflected the idea 
that "a sequence of tests" should be carried out before pro-
ceeding to biopsy. Although five people chose a level of 
3 ng/mL as their preferred option, three people commented 
that trials have shown using a level of 3 ng/mL will mean 
that some aggressive cancers are missed.
The next question asked respondents, if a screen-
ing programme were to be implemented, what further 
investigation(s) they thought men with a raised PSA level 
should have prior to being offered biopsy. Multiple options 
could be chosen. The most popular option was mpMRI 
with 16 respondents (80%) indicating that they thought 
this should be used prior to biopsy. Seven out of 20 (35%) 
respondents indicated that a multi-kallikrein panel (e.g. 
4kscore, STHLM3) should be used, either with mpMRI 
alone (4 participants) or alongside PSA density, percent free 
PSA and mpMRI (3 participants). Six chose digital rectal 
examination (DRE) as an option (Fig. 3d). Other responses 
were ’no screening’ and ’polygenic markers’. All three GPs 
indicated that they thought mpMRI should be used prior to 
biopsy, as did all participants from Sweden, the Netherlands 
and nine out of ten participants from the UK. All four of 
those involved in public health or research thought that DRE 
should be offered.
3.1.4  How Frequently to Screen?
The final question asked the participants who favoured 
screening over no screening how often they thought men 
should be screened, given their optimal screening strategy. 
The options were every 10, 6, 4, and 2 years, annually, only 
once, and ’this should be based on PSA level’. No partici-
pants chose 10 years, 6 years or only once as an appropriate 
interval and only one participant chose each of 4 years, 2 
years and annually. The most popular responses were ’this 
should be based on PSA level’ and ’other’ (Fig. 3e).
Of those who thought that screening interval should be 
based on PSA level, all stated that men with a PSA level 
<3 ng/mL could be screened every 2–3 years whereas men 
with a higher PSA should be screened annually. In the 
’other’ column, the suggestions made were mainly around 
screening interval being based on risk.
In summary, the responses to Round 1 indicated several 
items that were not of interest to the clinical experts sur-
veyed in this sample and therefore assumed to not be of 
interest to compare in a cost-effectiveness model. These 
included opportunistic screening, a PSA threshold for fur-
ther investigation > 3 or a fixed screening interval for all 
men, as these were not chosen by any participant. On the 
other hand, a clear consensus (in terms of the pre-defined 
criteria of >70% agreement) was shown towards the exami-
nation of the use of mpMRI prior to biopsy in any potential 
screening strategy.
3.2  Round 2
The results from Round 1 formed the basis of Round 2, 
which was a set of 13 consensus statements designed to 
clarify the expert’s responses. As interest was shown in all 
three of no screening, age-based and risk-based strategies, 
respondents were again asked their opinion on each but 
this time in the context of their inclusion as comparators 
in a cost-effectiveness model. Similarly, further statements 
attempted to clarify the respondent’s views on the inclusion 
of PSA/other biomarker testing in the screening pathways 
to be considered in a cost-effectiveness model and how 
screening intervals should be determined. Seventeen of the 
20 participants who completed Round 1 also responded to 
Round 2, giving an 85% response rate. The participants were 
again from a wide and representative range of backgrounds 
(Fig. 4).
The statements that participants were asked to indicate 
their agreement with are shown in Table 1. This table also 
shows the percentage of participants rating a statement 7–9 
(moderately agree, agree, or strongly agree). A threshold 
of 70% in this category was the pre-agreed marker of con-
sensus. The percentage of patients rating a statement 8–9 
is also shown as well as the percentage rating a statement 
1–3 (strongly disagree, disagree or moderately disagree). 
Detailed results for each statement are given in Supplemen-
tary material 4 (see ESM).
Consensus was considered reached, under both the pre-
agreed rules (> 70% scoring an item 7–9 and < 15% scoring 
1–3) and the more stringent rules (> 70% scoring an item 8 
or 9 and < 15% scoring 1–3) on the following five strategies 
to compare in a cost-effectiveness model:
1. No screening
2. Inviting all men within a certain age range to be screened
3. Inviting only higher risk men for screening (if it is pos-
sible to identify higher risk men through the use of poly-
genic risk scores, family history, ethnicity or otherwise)
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4. Inviting all men within a certain age bracket for screen-
ing, but screening higher risk men at an earlier age
5. Using different screening intervals for higher and lower 
risk men
  Consensus was also considered reached under the pre-
agreed criteria, but not the more stringent criteria, on
6. Using different screening intervals based on PSA level 
at previous test
For all of these strategies, interrater agreement was con-
sidered high (>0.8).
Consensus was not considered reached on comparing 
aspects relating to PSA and other biomarker testing. The 
responses suggest that participants did not agree on whether 
PSA in isolation should be used as a reflex test, whether 
a PSA test should be used alongside a more sophisticated 
biomarker or risk model, whether a PSA threshold of 1.5 ng/
mL has enough negative predictive value to exclude any fur-
ther testing or whether the threshold for further investigation 
should increase as men age. In all four of these statements, 
over 35% of respondents indicated agreement but at least 
5% indicated disagreement. Comments mainly addressed the 
need for additional and reliable evidence. There was also 
uncertainty as to the added benefit of biomarkers over the 
use of MRI.
Although consensus was not considered reached on 
whether reflex tests such as multi-kallikrein panels, risk 
models, PSA density or percent free PSA should be evalu-
ated for incorporation in potential screening strategies, there 
was a tendency towards agreement rather than disagreement 
with no participants rating either of these statements 1–3. 
Concerns raised in the comments again centred around a 
lack of reliable evidence.
With regard to the question of whether all men being 
screened should be offered a DRE, there was a clear tendency 
towards disagreement with only 18% of participants being in 
agreement and 47% disagreeing, suggesting that DRE should 
not be included when evaluating potential screening strate-
gies. Concerns raised with offering all men a DRE included 
deterring patients and a high false positive rate.
Fig. 4  Characteristics of respondents—Round 2
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Table 1  Final outcomes for statements after Round 2
DRE digital rectal examination, mpMRI multiparametric magnetic resonance imaging, PSA prostate-specific antigen, STHLM3 Stockholm 3 
panel
*This was the only statement for which the outcome under the more stringent rules differed i.e., consensus not reached
Statement % Rating 7–9 % Rating 8–9 % Rating 1–3 Outcome: pre-agreed rules Interrater 
agreement 
 (r*wg)
It is useful to compare the cost-effectiveness of no 
screening to other screening strategies in a future 
economic model
88.24 88.24 0.00 Consensus reached 0.90
It is useful to compare the cost-effectiveness of invit-
ing all men within a certain age range to be screened 
to other screening strategies in a future economic 
model
94.12 82.35 5.88 Consensus reached 0.89
If it is possible to identify men at higher risk of devel-
oping prostate cancer prior to testing (through the 
use of polygenic risk scores, family history, ethnicity 
or otherwise), it would be useful to compare the 
cost-effectiveness of inviting only higher risk men 
for screening
88.24 82.35 0.00 Consensus reached 0.94
If it is possible to identify men at higher risk of devel-
oping prostate cancer prior to testing, it would be 
useful to compare the cost-effectiveness of inviting 
all men within a certain age bracket for screening 
but screening higher risk men at an earlier age
88.24 70.59 5.88 Consensus reached 0.82
PSA in isolation should no longer be used a reflex test 
to trigger MRI/prostate biopsy
35.29 23.53 17.65 Consensus not reached 0.75
A PSA test should be used before a more sophisticated 
biomarker or risk model (e.g. 4k score, STHLM3) 
and only men with total PSA above a certain 
threshold should be tested using the biomarker or 
risk model
41.18 35.29 23.53 Consensus not reached 0.65
A PSA threshold of 1.5 ng/ml has enough negative 
predictive value to exclude any further testing
35.29 23.53 17.65 Consensus not reached 0.65
The threshold for further investigation should increase 
as men age
47.06 35.29 5.88 Consensus not reached 0.76
It would be useful to assess the cost-effectiveness of 
using a multi-kallikrein panel or risk model (e.g. 4k 
score, STHLM3) as a reflex test to triage patients 
suitable for mpMRI prior to biopsy
64.71 52.94 0.00 Consensus not reached 0.87
It would be useful to assess the cost-effectiveness 
of using PSA density and % free PSA alongside 
a multi-kallikrein panel as reflex tests to triage 
patients suitable for mpMRI prior to biopsy
52.94 41.18 0.00 Consensus not reached 0.89
All men being screened should be offered a DRE 17.65 17.65 47.06 Consensus not reached 0.59
If it is possible to identify men at higher risk of devel-
oping prostate cancer (through the use of polygenic 
risk scores, family history, ethnicity or otherwise), 
it would be useful to compare the cost-effectiveness 
of using different screening intervals for higher and 
lower risk men
88.24 82.35 0.00 Consensus reached 0.93
It is useful to compare the cost-effectiveness of using 
different screening intervals based on PSA level at 
previous test
76.47 64.71 0.00 Consensus reached* 0.89
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4  Discussion
Our aim was to illustrate a method, using prostate cancer 
screening as an exemplar, to identify strategies to be evalu-
ated in cost-effectiveness modelling when there is consider-
able uncertainty surrounding the relevant comparators (deci-
sion question uncertainty). This process has highlighted the 
uncertainty and diverging views that can exist and a means 
to focus these views. We have endeavoured to elicit views 
from experts working in the field, in accordance with guide-
lines, and to ensure the findings are applicable to decision 
makers.
This is the first study to both use and illustrate how to 
use a modified Delphi method to handle decision question 
uncertainty and identify relevant comparators for a cost-
effectiveness analysis in a rapidly evolving decision-making 
context. However, the method has previously been used to 
define the boundaries of a model, in model conceptualisa-
tion, and to identify face validity [29–31].
Overall agreement was obtained on the patient charac-
teristics and screening technologies to consider in cost-
effectiveness modelling. Although the panel did not reach 
consensus on exact age ranges to screen or a specific screen-
ing interval, future cost-effectiveness models could explore 
different combinations of screening stopping/starting ages 
and intervals within the limits suggested by the participants. 
This could identify the most cost-effective combination of 
these strategies to enable assessment of whether the ‘optimal 
combination strategy’ could be cost effective compared with 
current practice (opportunistic screening).
One strength of the study was the panel of experts, who 
had a wide range of experience. Relying solely on one pro-
ject team to identify relevant strategies may have resulted 
in biased or outdated views. The modified Delphi method 
provided a systematic way to gain consensus (according 
to the predefined criteria) from a wide variety of experts. 
The web-based format enabled the inclusion of views from 
respondents from geographically dispersed locations. The 
anonymity meant that no one voice was given precedence 
and experts had time to consider their responses. An addi-
tional advantage was the relative speed of the process, ensur-
ing relevancy in the context of newer innovations.
The aim of any future cost-effectiveness analysis should 
be to determine, not which screening strategy is most cost 
effective, but rather if any of the identified screening strate-
gies have the potential to be more cost effective than current 
practice (i.e. opportunistic PSA-based screening). This can be 
determined by exploring which aspects of the screening path-
way have the potential to impact on mortality, overdiagnosis 
and diagnostic and treatment harms, if improved. A further 
strength is that the findings from the Delphi can be used to 
focus future research to provide evidence on aspects of the 
identified screening strategies that experts feel are important.
A limitation of the web-based format was the inability to 
have an in-depth response from respondents on the meaning 
and reasoning behind their answers as would be possible in 
a face-to-face interview setting, although in most cases the 
participants provided substantial and helpful comments. A 
further limitation is that the snowball approach may have led 
to researchers only recommending others they agree with, 
reinforcing any bias in the initial sample. There is also a 
concern that relevant potentially effective and cost-effective 
alternatives may have been missed or deliberately excluded 
by experts if they were not options that they themselves 
would support. We attempted to mitigate this by sending an 
evidence dossier to participants in advance to ensure they 
were aware of any relevant evidence and also by selecting 
participants with varying expertise and from a variety of 
institutions and countries to encourage diversity of opinions. 
We acknowledge, however, that there is still a potential risk 
of missing relevant aspects when using expert opinion rather 
than empirical evidence.
The choice to ask participants to indicate their preferred 
strategy in Round 1 did not allow us to estimate numerical 
uncertainty in their answers. However, participants were 
encouraged to comment on their answers, which is where 
any uncertainty was made clear. In the second round, par-
ticipant’s uncertainty could be more clearly drawn out as 
they were requested to rank their agreement with the state-
ments on a 9-point Likert scale. A further potential limita-
tion is that the study aimed to achieve consensus on relevant 
screening strategies from participants from different coun-
tries with different health care systems. In general, the cur-
rent standard of care in a particular health care setting may 
influence the set of comparators chosen, which could make 
incorporating an international perspective difficult. This is 
less of an issue in prostate cancer screening as current prac-
tice in the UK, Europe and the US is a generally consistent 
policy of shared decision making around whether or not a 
man undergoes PSA testing with a recommendation against 
formal screening. The limitations of an international per-
spective should be weighed against the benefits in any future 
applications, however.
Whilst the Delphi panel has identified screening strate-
gies to assess in a cost-effectiveness analysis, there is lim-
ited or no trial evidence on several of the suggested strate-
gies. This was highlighted by the participants throughout 
the process. When trial data are not available, as is often 
the case in screening due to the sample size required and 
associated expense, model-based economic evaluations are 
commonly used. Mathematical models can combine the 
best available sources of evidence on different aspects of 
screening to predict the costs and consequences of their use 
[32, 33]. However, it is important to take full account of the 
uncertainty in this evidence to prevent misguided conclu-
sions. Any future cost-effectiveness model should consider 
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this uncertainty and enable adaption when new information 
becomes available.
5  Conclusion
The modified Delphi process identified six screening strate-
gies that are relevant for comparing in a cost-effectiveness 
analysis against current practice (opportunistic screening). 
These strategies include no screening, age-based screening 
and different risk-stratified approaches, with all incorpo-
rating MRI. The work has demonstrated that the modified 
Delphi method could be used to identify relevant compara-
tors for cost-effectiveness models when there is uncertainty 
due to rapidly evolving technologies. It may also be used 
to direct future research towards gathering evidence in the 
identified comparator pathways.
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